m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01026)
Name
RDP58
Synonyms
Delmitide; RDP58; RDP-58; UNII-5759XTJ706; 5759XTJ706; Delmitide [INN]; Allotrap-1258; Allotrap 1258; 287096-87-1; AC1L55WS; AC1Q5JM9; (2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-5-guanidino-pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-n-[(1r)-1-[[(1r)-1-[[(1r)-1-[[(1r)-1-[[2-[[(1r)-2-amino-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-2-oxo-ethyl]carbamoyl]pentyl]carbamoyl]pentyl]carbamoyl]pentyl]carbamoyl]-4-guanidino-butyl]hexanamide; RDP 58; RSP-58; SCHEMBL18758870; D-Tyrosinamide, D-arginyl-D-norleucyl-D-norleucyl-D-n
    Click to Show/Hide
Status
Phase 2
Structure
3D MOL
2D MOL
Formula
C59H105N17O11
InChI
1S/C59H105N17O11/c1-7-13-22-40(51(81)68-36-48(78)69-47(49(61)79)35-37-29-31-38(77)32-30-37)71-53(83)42(24-15-9-3)73-55(85)44(26-17-11-5)75-57(87)46(28-20-34-67-59(64)65)76-56(86)45(27-18-12-6)74-54(84)43(25-16-10-4)72-52(82)41(23-14-8-2)70-50(80)39(60)21-19-33-66-58(62)63/h29-32,39-47,77H,7-28,33-36,60H2,1-6H3,(H2,61,79)(H,68,81)(H,69,78)(H,70,80)(H,71,83)(H,72,82)(H,73,85)(H,74,84)(H,75,87)(H,76,86)(H4,62,63,66)(H4,64,65,67)/t39-,40-,41-,42-,43-,44-,45-,46-,47-/m1/s1
InChIKey
SFGFYNXPJMOUHK-PKAFTLKUSA-N
PubChem CID
219021
TTD Drug ID
D0A8JM
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Tumor necrosis factor (TNF)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tumor necrosis factor (TNF) is a therapeutic target for RDP58. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of RDP58 through regulating the expression of Tumor necrosis factor (TNF). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tumor necrosis factor (TNF) is a therapeutic target for RDP58. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of RDP58 through regulating the expression of Tumor necrosis factor (TNF). [2], [3]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tumor necrosis factor (TNF) is a therapeutic target for RDP58. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RDP58 through regulating the expression of Tumor necrosis factor (TNF). [2], [4]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tumor necrosis factor (TNF) is a therapeutic target for RDP58. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of RDP58 through regulating the expression of Tumor necrosis factor (TNF). [2], [4]
YTH domain-containing family protein 3 (YTHDF3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tumor necrosis factor (TNF) is a therapeutic target for RDP58. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of RDP58 through regulating the expression of Tumor necrosis factor (TNF). [1], [2]
References
Ref 1 N6-methyladenosine reader YTH N6-methyladenosine RNA binding protein 3 or insulin like growth factor 2 mRNA binding protein 2 knockdown protects human bronchial epithelial cells from hypoxia/reoxygenation injury by inactivating p38 MAPK, AKT, ERK1/2, and NF-KappaB pathways. Bioengineered. 2022 May;13(5):11973-11986. doi: 10.1080/21655979.2021.1999550.
Ref 2 Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci. 2009 Feb;50(2):771-8. doi: 10.1167/iovs.08-2370. Epub 2008 Aug 29.
Ref 3 METTL14 promotes glomerular endothelial cell injury and diabetic nephropathy via m6A modification of Alpha-klotho. Mol Med. 2021 Sep 9;27(1):106. doi: 10.1186/s10020-021-00365-5.
Ref 4 Mettl3 inhibits the apoptosis and autophagy of chondrocytes in inflammation through mediating Bcl2 stability via Ythdf1-mediated m(6)A modification. Bone. 2022 Jan;154:116182. doi: 10.1016/j.bone.2021.116182. Epub 2021 Sep 13.